{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:11:37Z","timestamp":1779372697336,"version":"3.53.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.therap.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:13:49Z","timestamp":1752574429000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mise en place d\u2019un sevrage de benzodiaz\u00e9pines avec substitution par le praz\u00e9pam\u00a0: \u00c9tude r\u00e9trospective aupr\u00e8s de 86\u00a0patients"],"prefix":"10.1016","volume":"81","author":[{"given":"Amir Kallab","family":"Debbih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Cutarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Spadari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.06.008_bib0190","unstructured":"ANSM. \u00c9tat des lieux de la consommation des benzodiazepines en France. Avril 2017. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Etat-des-lieux-de-la-consommation-des-benzodiazepines-Point-d-Information.[Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0195","first-page":"748","article-title":"Usages et bon usage des benzodiaz\u00e9pines anxiolytiques et hypnotiques","volume":"179","author":"Bonnay","year":"2021","journal-title":"Ann Med Psychol"},{"key":"10.1016\/j.therap.2025.06.008_bib0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.therap.2022.12.005","article-title":"Trends in use of benzodiazepines and Z-drugs in France from 2012\u00a0to 2020","volume":"78","author":"B\u00e9nard-Laribi\u00e8re","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.06.008_bib0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.therap.2018.09.071","article-title":"Impact des benzodiaz\u00e9pines sur les fonctions cognitives et le risque de d\u00e9mence Revue des arguments de causalit\u00e9 issus des \u00e9tudes observationnelles","volume":"74","author":"Lapeyre-Mestre","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.06.008_bib0210","unstructured":"HAS. Arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s: d\u00e9marche du m\u00e9decin traitant en ambulatoire. Juin 2015. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2015-06\/fiche_memo_rapport_elaboration_arret_benzodiazepines__2015_06_17.pdf. [Consult\u00e9 le 30\u00a0juin 2025 (60\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.06.008_bib0215","unstructured":"HAS. Fiche m\u00e9mo - Arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s: d\u00e9marche du m\u00e9decin traitant en ambulatoire. 2015. https:\/\/www.has-sante.fr\/jcms\/c_2038262\/fr\/arret-des-benzodiazepines-et-medicaments-apparentes-demarche-du-medecin-traitant-en-ambulatoire.[Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0220","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2025.06.008_bib0225","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/add.15695","article-title":"Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications","volume":"117","author":"Baldwin","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2025.06.008_bib0230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.06.008_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The epidemiology of benzodiazepine misuse: A systematic review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2025.06.008_bib0240","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.therap.2023.02.002","article-title":"Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011\u00a0to 2020","volume":"78","author":"Diaz","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.06.008_bib0245","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/fcp.12678","article-title":"Characterization of benzodiazepine misuse and comorbidities in patients with alcohol use disorder","volume":"35","author":"Lopez","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.06.008_bib0250","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/YIC.0b013e32834967e5","article-title":"Monitoring of benzodiazepine diversion using a multi-indicator approach","volume":"26","author":"Pauly","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.06.008_bib0255","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/add.16261","article-title":"Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: A nation-wide, repeated cross-sectional study","volume":"118","author":"Soeiro","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2025.06.008_bib0260","doi-asserted-by":"crossref","first-page":"102507","DOI":"10.1016\/j.eclinm.2024.102507","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review","volume":"70","author":"Brandt","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.therap.2025.06.008_bib0265","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1192\/bjp.178.4.317","article-title":"Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off: Report on behalf of the Dutch Chronic Benzodiazepine Working Group","volume":"178","author":"Zitman","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.therap.2025.06.008_bib0270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/fampra\/cmab143","article-title":"Discontinuation of chronic benzodiazepine use in primary care: a nonrandomized intervention","volume":"39","author":"Fernandes","year":"2022","journal-title":"Fam Pract"},{"key":"10.1016\/j.therap.2025.06.008_bib0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4236\/ojpsych.2016.62024","article-title":"Original and simple protocol for withdrawal of benzodiazepines to achieve sustained remission","volume":"6","author":"Philippe","year":"2016","journal-title":"Open Journal of Psychiatry"},{"key":"10.1016\/j.therap.2025.06.008_bib0280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1360-0443.1987.tb01529.x","article-title":"Benzodiazepine withdrawal: outcome in 50\u00a0patients","volume":"82","author":"Ashton","year":"1987","journal-title":"Br J Addict"},{"key":"10.1016\/j.therap.2025.06.008_bib0285","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ADM.0000000000001334","article-title":"Treating benzodiazepine withdrawal in a Bridge xlinic","volume":"18","author":"Laks","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2025.06.008_bib0290","unstructured":"VIDAL. HOPTIMAL. 2025. https:\/\/hoptimal.vidal.fr\/.[Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199001000-00006","article-title":"Comparison of the effect of two prazepam formulations on psychomotor and cognitive function in healthy volunteers","volume":"5","author":"Girre","year":"1990","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.06.008_bib0300","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00563121","article-title":"Pharmacokinetics of prazepam in man","volume":"16","author":"Smith","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.06.008_bib0305","first-page":"433","article-title":"A multi-centre comparison of prazepam and diazepam in the treatment of anxiety","volume":"3","author":"Dorman","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"10.1016\/j.therap.2025.06.008_bib0310","first-page":"411","article-title":"Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam","volume":"45","author":"Shader","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2025.06.008_bib0315","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.1988.158","article-title":"Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo","volume":"44","author":"Greenblatt","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2025.06.008_bib0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0893-133X(98)00052-9","article-title":"Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788\u00a0binding reflect selectivity for \u03b11\u00a0versus \u03b12\u00a0and \u03b13\u00a0subunit-containing GABAA receptors","volume":"20","author":"Atack","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.therap.2025.06.008_bib0325","first-page":"958","article-title":"Withdrawal from long-term benzodiazepine use: randomised trial in family practice","volume":"56","author":"Vicens","year":"2006","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.therap.2025.06.008_bib0330","unstructured":"Haute autorit\u00e9 de sant\u00e9. Modalit\u00e9s d\u2019arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s chez le patient \u00e2g\u00e9. 2008. https:\/\/www.has-sante.fr\/jcms\/c_601509\/fr\/modalites-d-arret-des-benzodiazepines-et-medicaments-apparentes-chez-le-patient-age. [Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0335","unstructured":"benzo.org.uk. Benzodiazepine Equivalence Table. 2007. https:\/\/www.benzo.org.uk\/bzequiv.htm.[Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0340","unstructured":"Grandjean C, Crettol S, Wavre F, Vandenberghe N, Ansermot G, Sibailly C, et al. Tableau comparatif des benzodiaz\u00e9pines et agonistes aux r\u00e9cepteurs des benzodiaz\u00e9pines. https:\/\/www.chuv.ch\/fileadmin\/sites\/dp\/documents\/tableau_comparatif_BZD_et_switch_rupture.pdf.[Consult\u00e9 le 30\u00a0juin 2025 (4\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.06.008_bib0345","unstructured":"Micromedex\u00ae (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Calculators\/benzodiazepine dosing conversions. 2025. https:\/\/www.micromedexsolutions.com\/. [Consult\u00e9 le 30\u00a0juin 2025]."},{"key":"10.1016\/j.therap.2025.06.008_bib0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0755-4982(06)74647-4","article-title":"Sevrage aux benzodiaz\u00e9pines des sujets d\u00e9pendants aux opiac\u00e9s en traitement de substitution","volume":"35","author":"Fats\u00e9as","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2025.06.008_bib0355","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.pharma.2009.07.001","article-title":"Benzodiazepine dependence: Focus on withdrawal syndrome","volume":"67","author":"Authier","year":"2009","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.therap.2025.06.008_bib0360","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamapsychiatry.2022.1150","article-title":"Complex persistent benzodiazepine dependence-when benzodiazepine deprescribing goes awry","volume":"79","author":"Peng","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2025.06.008_bib0365","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.NPR.0000733684.24949.19","article-title":"Best practices in benzodiazepine prescribing and management in primary care","volume":"46","author":"Champion","year":"2021","journal-title":"Nurse Pract"},{"key":"10.1016\/j.therap.2025.06.008_bib0185","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00228-022-03388-x","article-title":"Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure","volume":"78","author":"Basi\u0144ska-Szafra\u0144ska","year":"2022","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:36:48Z","timestamp":1779370608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0040595725001015"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.06.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mise en place d\u2019un sevrage de benzodiaz\u00e9pines avec substitution par le praz\u00e9pam\u00a0: \u00c9tude r\u00e9trospective aupr\u00e8s de 86\u00a0patients","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}